Tosh Dilip K, Paoletta Silvia, Phan Khai, Gao Zhan-Guo, Jacobson Kenneth A
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810.
ACS Med Chem Lett. 2012 Jul 12;3(7):596-601. doi: 10.1021/ml300107e. Epub 2012 Jun 11.
C2-Arylethynyladenosine-5'-N-methyluronamides containing a bicyclo[3.1.0]hexane ((N)-methanocarba) ring are selective A(3) adenosine receptor (AR) agonists. Similar 4'-truncated C2-arylethynyl-(N)-methanocarba nucleosides containing alkyl or alkylaryl groups at the N(6) position were low-efficacy agonists or antagonists of the human A(3)AR with high selectivity. Higher hA(3)AR affinity was associated with N(6)-methyl and ethyl (K(i) 3-6 nM), than with N(6)-arylalkyl groups. However, combined C2-phenylethynyl and N(6)-2-phenylethyl substitutions in selective antagonist 15 provided a K(i) of 20 nM. Differences between 4'-truncated and nontruncated analogues of extended C2-p-biphenylethynyl substitution suggested a ligand reorientation in AR binding, dominated by bulky N(6) groups in analogues lacking a stabilizing 5'-uronamide moiety. Thus, 4'-truncation of C2-arylethynyl-(N)-methanocarba adenosine derivatives is compatible with general preservation of A(3)AR selectivity, especially with small N(6) groups, but reduced efficacy in A(3)AR-induced inhibition of adenylate cyclase.
含有双环[3.1.0]己烷((N)-碳环)的C2-芳乙炔基腺苷-5'-N-甲基脲苷是选择性A(3)腺苷受体(AR)激动剂。类似的在N(6)位含有烷基或烷基芳基的4'-截短的C2-芳乙炔基-(N)-碳环核苷是人类A(3)AR的低效激动剂或拮抗剂,具有高选择性。与N(6)-芳烷基相比,N(6)-甲基和乙基(K(i) 3 - 6 nM)与更高的hA(3)AR亲和力相关。然而,选择性拮抗剂15中C2-苯乙炔基和N(6)-2-苯乙基的组合取代提供了20 nM的K(i)。扩展的C2-对-联苯乙炔基取代的4'-截短和非截短类似物之间的差异表明,在AR结合中配体重新定向,在缺乏稳定的5'-脲酰胺部分的类似物中,由庞大的N(6)基团主导。因此,C2-芳乙炔基-(N)-碳环腺苷衍生物的4'-截短与A(3)AR选择性的总体保留兼容,特别是对于小的N(6)基团,但在A(3)AR诱导的腺苷酸环化酶抑制中效力降低。